MARS: mutation-adjusted risk score for advanced systemic mastocytosis
1 Просмотры
• 07/09/23
0
0
встраивать
administrator
Подписчики
Andreas Reiter, MD, University Medical Centre, Mannheim, Germany, discusses how a mutation-adjusted risk score (MARS) may improve treatment stratification for advanced systemic mastocytosis (AdvSM). This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.
Показать больше
Комментарии Facebook
SORT BY-
Лучшие комментарии
-
Последние комментарии